The proposal to perform chemotherapy was based on the experience of other benign and intermediate malignant tumor in infancy which may show very different clinical courses. Therefore, it was very difficult to assess the expected effectiveness of chemotherapy in this rare entity. In addition, the tumor regression, if at all, could be expected to be very slow, so that the cumulative doses of the applied cytostatic drugs would be considerably high, which is unfavorable for infants. Cyclophosphamide, Actinomycin D or Vincristine were discussed here (8).